{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:23:53Z","timestamp":1793431433932,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA \u201cchemotherapy based\u201d and \u201cchemotherapy free\u201d protocols. Only de novo APL patients who achieved complete remission (CR) and completed the three consolidation cycles were enrolled into the analysis. Out of 2670 APL patients, there were 118 (4.4%) who developed s-NPLs with the median latency period (between first CR and diagnosis of s-NPL) of 48.0 months (range 2.8\u2013231.1): 43.3 (range: 2.8\u2013113.9) for s-MDS\/AML and 61.7 (range: 7.1\u2013231.1) for solid tumour. The 5-year CI of all s-NPLs was of 4.43% and 10 years of 7.92%. Among s-NPLs, there were 58 cases of s-MDS\/AML, 3 cases of other hematological neoplasms, 57 solid tumours and 1 non-identified neoplasm. The most frequent solid tumour was colorectal, lung and breast cancer. Overall, the 2-year OS from diagnosis of s-NPLs was 40.6%, with a median OS of 11.1 months. Multivariate analysis identified age of 35 years (hazard ratio = 0.2584;<jats:italic>p<\/jats:italic>&lt; 0.0001) as an independent prognostic factor for s-NPLs. There were no significant differences in CI of s-NPLs at 5 years between chemotherapy-based vs chemotherapy-free regimens (hazard ratio = 1.09;<jats:italic>p<\/jats:italic>= 0.932). Larger series with longer follow-up are required to confirm the potential impact of ATO+ATRA regimens to reduce the incidence of s-NPLs after front-line therapy for APL.<\/jats:p>","DOI":"10.1007\/s00277-023-05582-y","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T03:02:16Z","timestamp":1702954936000},"page":"451-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0781-8668","authenticated-orcid":false,"given":"Marta","family":"Sobas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Knopinska-Posluszny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Pi\u0105tkowska-Jakubas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena Amutio","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Gonz\u00e1lez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Algarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Salamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de la Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Sayas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Mateo","family":"Perez-Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Vidriales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana In\u00e9s","family":"Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Celebrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Brioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"de Laiglesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Bergua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luz","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodriguez-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Pluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Cichocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Skarupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"5582_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1053\/j.seminoncol.2008.04.010","volume":"35","author":"F Lo-Coco","year":"2008","unstructured":"Lo-Coco F, Ammatuna E, Montesinos P et al (2008) Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol 35:401\u2013409","journal-title":"Semin Oncol"},{"key":"5582_CR2","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","volume":"113","author":"MA Sanz","year":"2009","unstructured":"Sanz MA, Grimwade D, Tallman MS et al (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875\u20131891","journal-title":"Blood"},{"key":"5582_CR3","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","volume":"14","author":"P Fenaux","year":"1999","unstructured":"Fenaux P, Chastang C, Chevret S et al (1999) A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 14:1192\u20131200","journal-title":"Blood"},{"key":"5582_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","volume":"103","author":"MA Sanz","year":"2004","unstructured":"Sanz MA, Martin G, Gonzalez M et al (2004) Risk adapted treatment of acute promyelocytic leukemia with all trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103:1237\u20131243","journal-title":"Blood"},{"key":"5582_CR5","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1182\/blood-2010-01-266007","volume":"115","author":"MA Sanz","year":"2010","unstructured":"Sanz MA, Montesinos P, Rayon C et al (2010) Risk adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137\u20135146","journal-title":"Blood"},{"key":"5582_CR6","first-page":"1014","volume":"90","author":"F Mandelli","year":"1997","unstructured":"Mandelli F, Diverio D, Avvisati G et al (1997) Molecular remission in PML\/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90:1014\u20131021","journal-title":"Blood"},{"key":"5582_CR7","first-page":"3171","volume":"116","author":"E Lengfelder","year":"2010","unstructured":"Lengfelder E, Haferlach C, Saussele S et al (2010) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009;23:2248-58. Lo CoCo Blood 116:3171\u20133179","journal-title":"Lo CoCo Blood"},{"key":"5582_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","volume":"337","author":"MS Tallman","year":"1997","unstructured":"Tallman MS, Andersen JW, Schiffer CA et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021\u20131028","journal-title":"N Engl J Med"},{"key":"5582_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood.V72.2.567.567","volume":"72","author":"ME Huang","year":"1988","unstructured":"Huang ME, Ye YC, Chen SR et al (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:572","journal-title":"Blood"},{"key":"5582_CR10","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","volume":"107","author":"E Estey","year":"2006","unstructured":"Estey E, Garcia-Manero G, Ferrajoli A et al (2006) Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469\u20133473","journal-title":"Blood"},{"key":"5582_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 369:111\u2013121","journal-title":"N Engl J Med."},{"key":"5582_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L et al (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol 35:605\u2013612","journal-title":"J Clin Oncol"},{"key":"5582_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.leu.2403276","volume":"18","author":"L Pagano","year":"2004","unstructured":"Pagano L, Gimema F, Pulsoni A et al (2004) Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. Leukemia 18:651\u2013653","journal-title":"Leukemia"},{"key":"5582_CR14","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1200\/JCO.2010.29.2268","volume":"28","author":"P Montesinos","year":"2010","unstructured":"Montesinos P, Gonz\u00e1lez JD, Gonz\u00e1lez J et al (2010) Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 28:3872\u20133879","journal-title":"J Clin Oncol"},{"key":"5582_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/10428190290006044","volume":"43","author":"S Zompi","year":"2002","unstructured":"Zompi S, Vigui\u00e9 F (2002) Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma 43:275\u2013280","journal-title":"Leuk Lymphoma"},{"key":"5582_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ajh.21528","volume":"84","author":"C Batzios","year":"2009","unstructured":"Batzios C, Hayes LA, He SZ, Quach H, McQuilten ZK, Wall M, Campbell LJ (2009) Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. Am J Hematol 84:715\u2013719 Erratum in: Am J Hematol. 2010;85:550","journal-title":"Am J Hematol"},{"key":"5582_CR17","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/sj.leu.2403034","volume":"17","author":"I Lobe","year":"2003","unstructured":"Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, Ferrant A, Sanz M, Fey M, Chomienne C, Chevret S, Degos L, Fenaux P, European APL group experience (2003) Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 17:1600\u20131604","journal-title":"Leukemia"},{"key":"5582_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.V99.3.822","volume":"99","author":"R Latagliata","year":"2002","unstructured":"Latagliata R, Petti MC, Fenu S et al (2002) Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 99:822\u2013824","journal-title":"Blood"},{"key":"5582_CR19","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.3390\/cancers12123610","volume":"12","author":"L Lenzi","year":"2020","unstructured":"Lenzi L, Lee-Jones L, Mostofa MA, de Andrade DP, Ribeiro RC, Figueiredo BC (2020) Second primary malignancy after acute promyelocytic leukemia: a population-based study. Cancers (Basel) 12:3610","journal-title":"Cancers (Basel)"},{"key":"5582_CR20","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/s41375-020-0758-4","volume":"34","author":"S Kayser","year":"2020","unstructured":"Kayser S, Rahm\u00e9 R, Mart\u00ednez-Cuadr\u00f3n D et al (2020) Outcome of older (\u226570 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia 34:2333\u20132341","journal-title":"Leukemia"},{"key":"5582_CR21","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1038\/s41375-020-0905-y","volume":"34","author":"KJ Norsworthy","year":"2020","unstructured":"Norsworthy KJ, Avagyan A, Bird ST et al (2020) Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis. Leukemia 34:3082\u20133084","journal-title":"Leukemia"},{"key":"5582_CR22","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3109\/10428194.2014.953143","volume":"56","author":"A Eghtedar","year":"2015","unstructured":"Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F (2015) Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma 56:1342\u20131345","journal-title":"Leuk Lymphoma"},{"key":"5582_CR23","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2217\/fon-2017-0077","volume":"13","author":"S Giri","year":"2017","unstructured":"Giri S, Pathak R, Aryal MR et al (2017) Second primary malignancy in acute promyelocytic leukemia: a surveillance, epidemiology and end results database study. Futur Oncol 13:1455\u20131457","journal-title":"Futur Oncol"},{"key":"5582_CR24","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1182\/blood.V95.11.3273","volume":"95","author":"J Pedersen-Bjergaard","year":"2000","unstructured":"Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273\u20133279","journal-title":"Blood"},{"key":"5582_CR25","unstructured":"Pedersen-Bjergaard J, Philip P, Larsen SO et al (1993) Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7:1975\u20131986"},{"key":"5582_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev-pharmtox-010818-021031","volume":"59","author":"QY Chen","year":"2019","unstructured":"Chen QY, DesMarais T, Costa M (2019) Metals and mechanisms of carcinogenesis. Annu Rev Pharmacol Toxicol 59:537\u2013554","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5582_CR27","doi-asserted-by":"publisher","first-page":"113519","DOI":"10.1016\/j.ejmech.2021.113519","volume":"221","author":"G Liu","year":"2021","unstructured":"Liu G, Song Y, Li C et al (2021) Arsenic compounds: the wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology. Eur J Med Chem 221:113519","journal-title":"Eur J Med Chem"},{"key":"5582_CR28","unstructured":"Treatment of acute promyelocytic leukemia PETHEMA LPA 2012, PETHEMA\/PALG protocol"},{"key":"5582_CR29","unstructured":"Treatment of acute promyelocytic leukemia PETHEMA LPA 2017, PETHEMA\/PALG protocol"},{"key":"5582_CR30","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642\u20134649","journal-title":"J Clin Oncol"},{"key":"5582_CR31","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS et al (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133:1630\u20131643","journal-title":"Blood"},{"key":"5582_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"5582_CR33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/10428194.2018.1522438","volume":"60","author":"J Labrador","year":"2019","unstructured":"Labrador J, Lu\u00f1o E, Vellenga E et al (2019) Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leuk Lymphoma 60:1146\u20131155","journal-title":"Leuk Lymphoma"},{"key":"5582_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"5582_CR35","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163\u2013170","journal-title":"Cancer Chemother Rep"},{"key":"5582_CR36","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141\u20131154","journal-title":"Ann Stat"},{"key":"5582_CR37","doi-asserted-by":"crossref","unstructured":"Aalen O (1978) Nonparametric estimation of partial transition probabilities in multiple decrement models. Ann Stat 6:534\u2013545","DOI":"10.1214\/aos\/1176344198"},{"key":"5582_CR38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187\u2013220","journal-title":"J R Stat Soc B"},{"key":"5582_CR39","doi-asserted-by":"crossref","unstructured":"Morton LM, Onel K, Curtis RE et al (2014) The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book:e57\u2013e67","DOI":"10.14694\/EdBook_AM.2014.34.e57"},{"key":"5582_CR40","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood-2002-03-0962","volume":"100","author":"MK Andersen","year":"2002","unstructured":"Andersen MK, Pedersen-Bjergaard J (2002) Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 100:1928\u20131929 author reply 1929","journal-title":"Blood"},{"key":"5582_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3324\/haematol.2009.013243","volume":"95","author":"J Cervera","year":"2010","unstructured":"Cervera J, Montesinos P, Hern\u00e1ndez-Rivas JM et al (2010) Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica 95:424\u2013431","journal-title":"Haematologica"},{"key":"5582_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0165-4608(96)00323-8","volume":"97","author":"M Sessarego","year":"1997","unstructured":"Sessarego M, Fugazza G, Balleari E et al (1997) High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. Cancer Genet Cytogenet 97:161\u2013164","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"5582_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/ejh.13346","volume":"104","author":"M Sobas","year":"2020","unstructured":"Sobas M, Rodriguez-Veiga R, Vellenga E et al (2020) PETHEMA, HOVON, PALG, GATLA cooperative groups. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. Eur J Haematol. 104(3):162\u2013169","journal-title":"Eur J Haematol."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05582-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T08:29:14Z","timestamp":1730881754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05582-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["5582"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05582-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"29 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in present study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. The patient signed informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}